Since only 3.1% of the study population had a platelet level <50 x 103/μL, it remains unclear whether an even better relationship exists between the types of P2Y12 inhibitors and clinical outcomes of patients with AMI and severe thrombocytopenia. This evidence concerns the gene P2RY12 and Thrombocytopenia.